The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Proliferation Marker Ki-67 in Early Breast Cancer
Abstract
Molecular markers have been extensively investigated with a view to providing early and accurate information on long-term outcome and prediction of response to treatment of early breast cancer. Proliferation is a key feature of the progression of tumors and is now widely estimated by the immunohistochemical assessment of the nuclear antigen Ki-67. The expression of Ki-67 correlates with other measurements of proliferation, including S-phase and bromodeoxyuridine uptake. High Ki-67 is a sign of poor prognosis associated with a good chance of clinical response to chemotherapy, but its independent significance is modest and does not merit measurements in most routine clinical scenarios. However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Gerdes, J., Schwab, U., Lemke, H., & Stein, H. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910310104 · Cited by 2,788
Shi, S. R., Key, M. E., & Kalra, K. L. (1991) · Journal of Histochemistry & Cytochemistry · doi:10.1177/39.6.1709656 · Cited by 2,552
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Gerdes, J., Li, L., Schlueter, C. J., Duchrow, M., Wohlenberg, C., Gerlach, C., Stahmer, I., Kloth, S., Brandt, E., & Flad, H. D. (1991) · PubMed · Cited by 889
The ATAC (Arimidex, T. A. O. I. C. T. G. (2003) · Cancer · doi:10.1002/cncr.11745 · Cited by 861
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Blohmer, J.-U., Ashley, S. E., Francis, S., Boeddinghaus, I., & Walsh, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.005 · Cited by 774
Self-citationSchlüter, C., Duchrow, M., Wohlenberg, C., Becker, M. H., Key, G., Flad, H. D., & Gerdes, J. (1993) · The Journal of cell biology · doi:10.1083/jcb.123.3.513 · Cited by 765
Dissociation between steroid receptor expression and cell proliferation in the human breast.
Clarke, R. B., Howell, A., Potten, C. S., & Anderson, E. J. (1997) · PubMed · Cited by 625
Key, G., Becker, M., Baron, B., Duchrow, M., Schlüter, C., Flad, H. D., & Gerdes, J. (1993) · PubMed · Cited by 376
Bruno, S., & Darzynkiewicz, Z. (1992) · Cell Proliferation · doi:10.1111/j.1365-2184.1992.tb01435.x · Cited by 375
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.951s.11.2 · Cited by 348
Self-citationBreast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
Faneyte, I. F., Schrama, J. G., Peterse, J. L., Remijnse, P. L., Rodenhuis, S., & van de Vijver, M. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600749 · Cited by 307
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., Mansel, R. E., Blamey, R. W., Bundred, N. J., Robertson, J. F. R., & Saunders, C. M. (1994) · PubMed · Cited by 291
Self-citationEstrogen Receptor-Positive Proliferating Cells in the Normal and Precancerous Breast
Shoker, B. S., Jarvis, C., Clarke, R. B., Anderson, E., Hewlett, J., Davies, M. P. A., Sibson, D. R., & Sloane, J. P. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65498-3 · Cited by 278
Petit, T., Wilt, M., Velten, M., Millon, R., Rodier, J.-F., Borel, C., Mors, R., Haegelé, P., Eber, M., & Ghnassia, J.-P. (2004) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00675-0 · Cited by 264
Ki67 immunostaining in primary breast cancer: pathological and clinical associations
Bouzubar, N., Walker, K., Griffiths, K., Ellis, I., Elston, C., Robertson, J., Blamey, R., & Nicholson, R. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.200 · Cited by 259
Starborg, M., Gell, K., Brundell, E., & Höög, C. (1996) · Journal of Cell Science · doi:10.1242/jcs.109.1.143 · Cited by 230
Decensi, A., Robertson, C., Viale, G., Pigatto, F., Johansson, H., Kisanga, E. R., Veronesi, P., Torrisi, R., Cazzaniga, M., Mora, S., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.11.779 · Cited by 221
Robertson, J. F. R., Nicholson, R. I., Bundred, N. J., Anderson, E., Rayter, Z., Dowsett, M., Fox, J. N., Gee, J. M. W., Webster, A., Wakeling, A. E., et al. (2001) · PubMed · Cited by 216
Self-citationJoensuu, H., Isola, J. J., Lundin, M., Salminen, T. M., Holli, K., Kataja, V. V., Pylkkänen, L. H., Turpeenniemi-Hujanen, T. M., von Smitten, K., & Lundin, J. E. (2003) · PubMed · Cited by 207
Ellis, M. J., Coop, A., Singh, B., Yu, T., Llombart‐Cussac, A., Jänicke, F., Mauriac, L., Quebe‐Fehling, E., Chaudri‐Ross, H. A., Evans, D. B., et al. (2003) · PubMed · Cited by 202
Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes
Lopez, F., Belloc, F., Lacombe, F., Dumain, P., Reiffers, J., Bernard, P., & Boisseau, M. R. (1991) · Cytometry · doi:10.1002/cyto.990120107 · Cited by 193
Trihia, H., Murray, S., Price, K., Gelber, R. D., Golouh, R., Goldhirsch, A., Coates, A. S., Collins, J., Castiglione‐Gertsch, M., & Gusterson, B. A. (2003) · Cancer · doi:10.1002/cncr.11188 · Cited by 189
Spyratos, F., Ferrero‐Poüs, M., Trassard, M., Hacène, K., Phillips, E., Tubiana‐Hulin, M., & Le Doussal, V. (2002) · Cancer · doi:10.1002/cncr.10458 · Cited by 186
Kill, I. R. (1996) · Journal of Cell Science · doi:10.1242/jcs.109.6.1253 · Cited by 183
Pinder, S., Wencyk, P., Sibbering, D., Bell, J., Elston, C., Nicholson, R., Robertson, J., Blamey, R., & Ellis, I. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.30 · Cited by 179
van Dierendonck, J. H., Keijzer, R., van de Velde, C. J., & Cornelisse, C. J. (1989) · PubMed · Cited by 179
Nicholson, R. I., McClelland, R. A., Finlay, P., Eaton, C. L., Gullick, W. J., Dixon, A. R., Robertson, J. F. R., Blamey, R. W., & Ellis, I. O. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80215-1 · Cited by 178
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
Chang, J., Ormerod, M., Powles, T. J., Allred, D. C., Ashley, S. E., & Dowsett, M. (2000) · Cancer · doi:10.1002/1097-0142(20001201)89:11<2145::aid-cncr1>3.0.co;2-s · Cited by 173
Self-citationDowsett, M., Harper-Wynne, C. L., Boeddinghaus, I., Salter, J., Hills, M., Dixon, M., Ebbs, S. R., Gui, G. P., Sacks, N., & Smith, I. E. (2001) · PubMed · Cited by 172
Self-citationRelationship between labeling indices of KI-67 and brdurd in human malignant tumors
Sasaki, K., Matsumura, K., Tsuji, T., Shinozaki, F., & Takahashi, M. (1988) · Cancer · Cited by 172
Minichromosome Maintenance Protein 2 Is a Strong Independent Prognostic Marker in Breast Cancer
Gonzalez, M. A., Pinder, S. E., Callagy, G., Vowler, S. L., Morris, L. S., Bird, K., Bell, J. A., Laskey, R. A., & Coleman, N. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.121 · Cited by 158
Harper-Wynne, C. L., Ross, G., Sacks, N. P. M., Salter, J., Nasiri, N., Iqbal, J., A’Hern, R., & Dowsett, M. (2002) · PubMed · Cited by 138
Self-citationThor, A. D., Liu, S., Moore, D. H., & Edgerton, S. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.470 · Cited by 137
Malik, S. N., Siu, L. L., Rowinsky, E. K., deGraffenried, L. A., Hammond, L. A., Rizzo, J. D., Bacus, S. S., Brattain, M. G., Kreisberg, J. I., & Hidalgo, M. M. (2003) · PubMed · Cited by 130
Prosperi, E. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7_15 · Cited by 128
Ellis, P., Smith, I. E., DETRE, S. I., Burton, S., Salter, J., A’Hern, R., Walsh, G., Johnston, S. R. D., & Dowsett, M. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005933815809 · Cited by 126
Self-citationLiu, S., Edgerton, S. M., Moore, D. H., & Thor, A. D. (2001) · PubMed · Cited by 122
Braun, N., Papadopoulos, T., & Müller‐Hermelink, H. K. (1988) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02889998 · Cited by 119
Chang, J. C., Powles, T. J., Allred, D. C., Ashley, S. E., Makris, A., Gregory, R. K., Osborne, C. K., & Dowsett, M. (2000) · PubMed · Cited by 115
Self-citationGeisler, J., DETRE, S. I., Berntsen, H., Ottestad, L., Lindtjørn, B., Dowsett, M., & Lønning, P. E. (2001) · PubMed · Cited by 114
Self-citationClarke, R. B., Laidlaw, I. J., Jones, L., Howell, A., & Anderson, E. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.111 · Cited by 113
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
Linn, S. C., Pinedo, H. M., van Ark-Otte, J., van der Valk, P., Hoekman, K., Honkoop, A. H., Vermorken, J. B., & Giaccone, G. (1997) · International Journal of Cancer · Cited by 112
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.
Brown, R. W., Allred, C., Clark, G. M., Osborne, C. K., & Hilsenbeck, S. G. (1996) · PubMed · Cited by 109
Dowsett, M., Bundred, N. J., DeCensi, A., Sainsbury, R., Lu, Y., Hills, M. J., Cohen, F. J., Veronesi, P., O'Brien, M. E. R., Scott, T., et al. (2001) · PubMed · Cited by 109
Self-citationKi‐67 labeling in postmitotic cells defines different Ki‐67 pathways within the 2c compartment
du Manoir, S., Guillaud, P., Camus, E., Seigneurin, D., & Brugal, G. (1991) · Cytometry · doi:10.1002/cyto.990120511 · Cited by 102
The biology of neoadjuvant chemotherapy for breast cancer.
Cleator, S. J., Parton, M., & Dowsett, M. (2002) · Endocrine Related Cancer · doi:10.1677/erc.0.0090183 · Cited by 95
Self-citationMonoclonal antibodies Ki‐S3 and Ki‐S5 yield new data on the ‘Ki‐67’proteins
Heidebrecht, H. J., Buck, F., Haas, K., Wacker, H. H., & Parwaresch, R. M. (1996) · Cell Proliferation · doi:10.1111/j.1365-2184.1996.tb00984.x · Cited by 92
Seshadri, R., Leong, A. S. ‐., McCaul, K. A., Firgaira, F. A., Setlur, V., & Horsfall, D. J. (1996) · International Journal of Cancer · Cited by 90
Clahsen, P. C., de Velde, C. J. H. V., Duval, C., Pallud, C., Mandard, A. M., Delobelle-Deroïde, A., van den Broek, L., & van de Vijver, M. J. (1999) · European Journal of Surgical Oncology · doi:10.1053/ejso.1999.0657 · Cited by 90
Harper-Wynne, C. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.1026 · Cited by 90
Apoptosis in breast cancer: relationship with other pathological parameters.
Lipponen, P. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060013 · Cited by 79
Rudolph, P., Kühling, H., Alm, P., Fernö, M., Baldetorp, B., Olsson, H. L., & Parwaresch, R. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11132 · Cited by 77
Immunologic Proliferation Marker Ki-S2 as Prognostic Indicator for Lymph Node-Negative Breast Cancer
Rudolph, P., Alm, P., Heidebrecht, H. J., Bolte, H., Ratjen, V., Baldetorp, B., Fernö, M., Olsson, H. L., & Parwaresch, R. M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.3.271 · Cited by 73
The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the estrogen receptor
Bardon, S., Vignon, F., Derocq, D., et al. (1984) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(84)90004-2 · Cited by 72
Haerslev, T., Jacobsen, G. K., & Zedeler, K. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806492 · Cited by 70
García‐Estévez, L., Cuevas, J. M., Antón, A., Florián, J., López-Vega, J. M., Velasco, A., Lobo, F., Herrero, A., & Fortes, J. (2003) · PubMed · Cited by 69
Johnston, S. R. D., MacLennan, K., Sacks, N. P. M., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00327-2 · Cited by 69
Assersohn, L., Salter, J., Powles, T. J., A’Hern, R., Makris, A., Gregory, R. K., Chang, J. C., & Dowsett, M. (2003) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000003968.45511.3f · Cited by 69
Self-citationGaglia, P., Bernardi, A., Venesio, T., Caldarola, B., Lauro, D., Cappa, A. P. M., Calderini, P., & Liscia, D. S. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90284-m · Cited by 66
Pohl, G., Rudas, M., Taucher, S., Stranzl, T., Steger, G. G., Jakesz, R., Pirker, R., & Filipits, M. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1022165715043 · Cited by 63
Billgren, L. E. R. A.-M. A.-M. (1999) · Acta Oncologica · doi:10.1080/028418699431186 · Cited by 60
Johnston, S. R. D., Boeddinghaus, I., Riddler, S., Haynes, B. P., Hardcastle, I. R., Rowlands, M. G., Grimshaw, R., Jarman, M., & Dowsett, M. (1999) · PubMed · Cited by 58
Self-citationWeikel, W., Beck, T., Mitze, M., & Knapstein, P. G. (1991) · Breast Cancer Research and Treatment · doi:10.1007/bf01990030 · Cited by 55
Iacopetta, B. J., Grieu, F., Powell, B. L., et al. (1998) · PubMed · Cited by 53
Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.
Dowsett, M., Dixon, J. M., Horgan, K. J., Salter, J., Hills, M., & Harvey, E. (2000) · PubMed · Cited by 50
Self-citationBECK, T. M., Weller, E. E., Weikel, W., Brumm, C., Wilkens, C., & Knapstein, P. G. (1995) · Gynecologic Oncology · doi:10.1006/gyno.1995.1104 · Cited by 45
Rudolph, P., Alm, P., Olsson, H. L., Heidebrecht, H.-J., Fernö, M., Baldetorp, B., & Parwaresch, R. M. (2001) · Human Pathology · doi:10.1053/hupa.2001.22748 · Cited by 41
Bundred, N. J., Anderson, E., Nicholson, R. I., Dowsett, M., Dixon, J. M., & Robertson, J. F. R. (2002) · PubMed · Cited by 32
Self-citationWeikel, W., Brumm, C., Wilkens, C., Beck, T., & Knapstein, P. G. (1995) · PubMed · Cited by 20
Cited by
Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., Ellis, M., Henry, N. L., Hugh, J. C., Lively, T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr393 · Cited by 1,977
Self-citationde Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603756 · Cited by 959
Triple-negative breast cancer: therapeutic options
Cleator, S., Heller, W., & Coombes, R. C. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70074-8 · Cited by 882
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., & Walsh, G. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk020 · Cited by 665
Self-citationEllis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 653
Self-citation
Metadata
- Authors
- Urruticoechea, A., Smith, I. E., & Dowsett, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-10-01
- Volume
- 23
- Issue
- 28
- Pages
- 7212-7220
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1965814195
- Cited by
- 837
- References
- 72
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.